Richard Kefford

103.6k citations

354 papers · 20.4k indexed · 7 hit papers · h-index 74

Oncology top 0.05%
- Cutaneous Melanoma Detection and Management 96
- Cancer Immunotherapy and Biomarkers 63
- CAR-T cell therapy research 58
- HER2/EGFR in Cancer Research 28
Immunology top 0.5%
- Immunotherapy and Immune Responses 42
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 32
Molecular Biology top 0.2%
- Melanoma and MAPK Pathways 158
Computational Theory and Mathematics top 0.2%
- Computational Drug Discovery Methods 26

Co-authors: Georgina V. Long Richard A. Scolyer John F. Thompson Helen Rizos Alexander M. Menzies Matteo S. Carlino Graham J. Mann Lauren E. Haydu
Cited by: Oncology Immunology Cancer Research
Journals: Nature (1 paper)Cell (1 paper)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: Australia United States France

In The Last Decade

Richard Kefford

352 papers receiving 20.1k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2019 Annals of Oncology
2014 Clinical Cancer Research
2013 Cancer Discovery
2012 The Lancet
2012 Nature Communications
2011 Clinical Cancer Research
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by Richard Kefford

Since Specialization

Citations

This map shows the geographic impact of Richard Kefford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kefford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kefford more than expected).

Fields of papers citing papers by Richard Kefford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kefford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kefford. The network helps show where Richard Kefford may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard Kefford, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard Kefford Line = papers co-authored together Richard Kefford links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors Clinical Cancer Research ·Jenny Lee,Alexander M. Menzies,Matteo S. Carlino,Ashleigh C. McEvoy,Shahneen Sandhu,Alison M. Weppler,Russell J. Diefenbach,Sarah‐Jane Dawson,Richard Kefford,Michael Millward,Zeyad Al‐Ogaili,Thien Tra,Elin S. Gray,Stephen Q. Wong,Richard A. Scolyer,Georgina V. Long,Helen Rizos	2020	62
2	bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays Bioinformatics ·Kevin Wang,Alexander M. Menzies,Inês Pires da Silva,James S. Wilmott,Yibing Yan,Matthew Wongchenko,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Garth Tarr,Samuel Mueller,Jean Yang	2018	1
3	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy Clinical Cancer Research ·Su Yin Lim,Jenny Lee,Tuba N. Gide,Alexander M. Menzies,Alexander Guminski,Matteo S. Carlino,Edmond J. Breen,Jean Yang,Shila Ghazanfar,Richard Kefford,Richard A. Scolyer,Georgina V. Long,Helen Rizos	2018	271
4	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma Clinical Cancer Research ·Ricardo E. Vilain,Alexander M. Menzies,James S. Wilmott,Hojabr Kakavand,Jason Madore,Alexander Guminski,Elizabeth Liniker,Benjamin Y. Kong,Adam Cooper,Julie R. Howle,Robyn P.M. Saw,Valerie Jakrot,Serigne Lo,John F. Thompson,Matteo S. Carlino,Richard Kefford,Georgina V. Long,Richard A. Scolyer	2017	191
5	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma Journal of Clinical Oncology ·Caroline Robert,Antoni Ribas,Omid Hamid,Adil Daud,Jedd D. Wolchok,Anthony M. Joshua,Wen-Jen Hwu,Jeffrey S. Weber,Tara C. Gangadhar,Richard W. Joseph,Roxana Dronca,Amita Patnaik,Hassane M. Zarour,Richard Kefford,Peter Hersey,Jin Zhang,James R. Anderson,Scott J. Diede,Scot Ebbinghaus,F. Stephen Hodi	2017	336
6	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors Clinical Cancer Research ·Hojabr Kakavand,Robert V. Rawson,Gulietta M. Pupo,Jean Yang,Alexander M. Menzies,Matteo S. Carlino,Richard Kefford,Julie R. Howle,Robyn P.M. Saw,John F. Thompson,James S. Wilmott,Georgina V. Long,Richard A. Scolyer,Helen Rizos	2017	63
7	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study Clinical Cancer Research ·Peter Fox,Rosemary L. Balleine,Clara Lee,Bo Gao,Bavanthi Balakrishnar,Alexander M. Menzies,Shang Heng Yeap,Sayed Ali,Val Gebski,Pamela Provan,Sally Coulter,Christopher Liddle,Rina Hui,Richard Kefford,Jodi Lynch,Mark Wong,Nicholas Wilcken,Howard Gurney	2016	64
8	PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials Pigment Cell & Melanoma Research ·Jason Madore,Ricardo E. Vilain,Alexander M. Menzies,Hojabr Kakavand,James S. Wilmott,Jessica Hyman,Jennifer H. Yearley,Richard Kefford,John F. Thompson,Georgina V. Long,Peter Hersey,Richard A. Scolyer	2014	333
9	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients Clinical Cancer Research ·Matteo S. Carlino,Carina Fung,Hamideh Shahheydari,Jason R. Todd,Suzanah C. Boyd,Mal Irvine,Adnan Nagrial,Richard A. Scolyer,Richard Kefford,Georgina V. Long,Helen Rizos	2014	53
10	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impactbreakdown → Clinical Cancer Research ·Helen Rizos,Alexander M. Menzies,Gulietta M. Pupo,Matteo S. Carlino,Carina Fung,Jessica Hyman,Lauren E. Haydu,Branka Mijatov,Therese M. Becker,Suzanah C. Boyd,Julie R. Howle,Robyn P.M. Saw,John F. Thompson,Richard Kefford,Richard A. Scolyer,Georgina V. Long	2014	382
11	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) Clinical Cancer Research ·Katherine L. Nathanson,Anne‐Marie Martin,Bradley Wubbenhorst,Joel Greshock,Richard Letrero,Kurt D’Andrea,Steven O’Day,Jeffrey R. Infante,Gerald S. Falchook,Hendrik‐Tobias Arkenau,Michael Millward,Michael P. Brown,Anna C. Pavlick,Michael A. Davies,Bo Ma,Robert Gagnon,Martin Curtis,Peter F. Lebowitz,Richard Kefford,Georgina V. Long	2013	132
12	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	2013	715
13	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma Molecular Cancer Therapeutics ·Matteo S. Carlino,Kavitha Gowrishankar,Catherine A.B. Saunders,Gulietta M. Pupo,Stephanie Snoyman,Xu Dong Zhang,Robyn P.M. Saw,Therese M. Becker,Richard Kefford,Georgina V. Long,Helen Rizos	2013	61
14	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Cancer Discovery ·Hubing Shi,Aayoung Hong,Xiangju Kong,Richard C. Koya,Chunying Song,Gatien Moriceau,Willy Hugo,Clarissa C. Yu,Charles Ng,Thinle Chodon,Richard A. Scolyer,Richard Kefford,Antoni Ribas,Georgina V. Long,Roger S. Lo	2013	133
15	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor Journal of Clinical Oncology ·Kevin B. Kim,Richard Kefford,Anna C. Pavlick,Jeffrey R. Infante,Antoni Ribas,Jeffrey A. Sosman,Leslie A. Fecher,Michael Millward,Grant A. McArthur,Patrick Hwu,René González,Patrick A. Ott,Georgina V. Long,Olivia Gardner,Danièle Ouellet,Yanmei Xu,Douglas J. DeMarini,Ngocdiep T. Le,Kiran Patel,Karl D. Lewis	2012	356
16	Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma Clinical Cancer Research ·Alexander M. Menzies,Lauren E. Haydu,Lydia Visintin,Matteo S. Carlino,Julie R. Howle,John F. Thompson,Richard Kefford,Richard A. Scolyer,Georgina V. Long	2012	327
17	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma Journal of Clinical Oncology ·Keith T. Flaherty,Sandra J. Lee,Fengmin Zhao,Lynn M. Schuchter,Lawrence E. Flaherty,Richard Kefford,Michael B. Atkins,Philip D. Leming,John M. Kirkwood	2012	160
18	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors Cancer Discovery ·Hubing Shi,Gatien Moriceau,Xiangju Kong,Richard C. Koya,Ramin Nazarian,Gulietta M. Pupo,Antonella Bacchiocchi,Kimberly B. Dahlman,Bartosz Chmielowski,Jeffrey A. Sosman,Ruth Halaban,Richard Kefford,Georgina V. Long,Antoni Ribas,Roger S. Lo	2012	75
19	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanomabreakdown → Clinical Cancer Research ·James S. Wilmott,Georgina V. Long,Julie R. Howle,Lauren E. Haydu,Raghwa Sharma,John F. Thompson,Richard Kefford,Peter Hersey,Richard A. Scolyer	2011	507
20	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Clinical Cancer Research ·Ian D. Davis,Ben Brady,Richard Kefford,Michael Millward,Jonathan Cebon,Birte K. Skrumsager,Ulrik Mouritzen,Lasse Tengbjerg Hansen,Kresten Skak,Dorthe Lundsgaard,Klaus Stensgaard Frederiksen,Paul E.G. Kristjansen,Grant A. McArthur	2009	120

About Richard Kefford

Richard Kefford is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 354 papers that have together received 20.4k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (158 papers), Cutaneous Melanoma Detection and Management (96 papers), Cancer Immunotherapy and Biomarkers (63 papers), CAR-T cell therapy research (58 papers), Immunotherapy and Immune Responses (42 papers), Cancer Genomics and Diagnostics (32 papers), HER2/EGFR in Cancer Research (28 papers) and Computational Drug Discovery Methods (26 papers). The work is most often cited by research in Oncology (13.9k citations), Immunology (4.0k citations) and Cancer Research (2.7k citations). Richard Kefford has collaborated with scholars based in Australia, United States and France. Frequent co-authors include Georgina V. Long, Richard A. Scolyer, John F. Thompson, Helen Rizos, Alexander M. Menzies, Matteo S. Carlino, Graham J. Mann, Lauren E. Haydu, Peter Hersey and Antoni Ribas. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact